HEPA Key Statistics, Chart & Performance
The current stock price of HEPA is 0.318 USD. In the past month the price decreased by -24.64%. In the past year, price decreased by -99.51%.
HEPA Technical Analysis
HEPA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HEPA. HEPA has a bad profitability rating. Also its financial health evaluation is rather negative.
HEPA Financial Highlights
Over the last trailing twelve months HEPA reported a non-GAAP Earnings per Share(EPS) of -616. The EPS decreased by -4.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -817.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEPA Forecast & Estimates
HEPA Ownership
HEPA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.25 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.67 | 574.257B | ||
| MRK | MERCK & CO. INC. | 22.05 | 290.769B | ||
| PFE | PFIZER INC | 9.23 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.85 | 123.896B | ||
| ZTS | ZOETIS INC | 18.74 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.53 | 25.52B | ||
| VTRS | VIATRIS INC | 6.38 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.59 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.37 | 9.291B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HEPA
Company Profile
Hepion Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.
Company Info
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837 US
CEO: Robert Foster
Employees: 22
Phone: 17329024000
HEPION PHARMACEUTICALS INC / HEPA FAQ
What does HEPA do?
Hepion Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.
What is the current price of HEPA stock?
The current stock price of HEPA is 0.318 USD. The price decreased by -18.79% in the last trading session.
Does HEPA stock pay dividends?
HEPA does not pay a dividend.
What is the ChartMill technical and fundamental rating of HEPA stock?
HEPA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of HEPA stock?
HEPION PHARMACEUTICALS INC (HEPA) operates in the Health Care sector and the Pharmaceuticals industry.